6/3/21, 11:00 AM
America/New York GMT -4 summer
VolitionRx (NYSE: VNRX) is a multinational epigenetics company developing simple, easy-to-use, cost-effective blood tests to help diagnose a range of cancers and other diseases in both humans and animals. The tests are based on the science of Nucleosomics, which is the practice of identifying and measuring nucleosomes in the bloodstream or other bodily fluid – an indication that disease is present. VolitionRx is primarily focused on human diagnostics, but also has a subsidiary focused on animal diagnostics.
Please join us for a conversation with chief executive officer Cameron Reynolds at 8:00am EST on Thursday 3 June. A brief update on the company’s recent operating activities will be followed by an open Q&A session.
Previous registration necessary?
Simultaneous translation ?
Will it be recorded?